Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 juil. 2026 08h45 HE | Source: Amplia Therapeutics Limited

Amplia Announces Publication of New FAK Inhibitor Patent Application

HIGHLIGHTS New patent application published covering chemically novel FAK inhibitors discovered by AmpliaApplication expands Amplia’s intellectual property portfolio supporting its FAK inhibitor...
07 juil. 2026 08h45 HE | Source: Amplia Therapeutics Limited

Amplia Announces Appointment of Brett Carter to Board

Melbourne, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce the appointment of Mr Brett Carter to...
06 juil. 2026 08h45 HE | Source: Amplia Therapeutics Limited

Amplia Announces Changes to Board’s Leadership Roles

Melbourne, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), announces Board changes further to a Board renewal and...
22 juin 2026 08h45 HE | Source: Amplia Therapeutics Limited

Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer

Melbourne, Australia, June 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX | OTCQB:INNMF), (“Amplia” or the “Company”) provides a letter to shareholders from CEO and Managing...